Connor, Clark & Lunn Investment Management (CC&L)
SIOX

Connor, Clark & Lunn Investment Management (CC&L)’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-18,066
Closed -$23K – 1274
2021
Q4 		$23K Sell
18,066
-114,255
-86% -$203K ﹤0.01% 1054
2021
Q3 		$287K Sell
132,321
-40,763
-24% -$88.6K ﹤0.01% 881
2021
Q2 		$473K Sell
173,084
-3,657
-2% -$9.09K ﹤0.01% 799
2021
Q1 		$461K Buy
176,741
+58,909
+50% +$167K ﹤0.01% 801
2020
Q4 		$328K Buy
+117,832
New +$343K ﹤0.01% 778
2019
Q1 		– Sell
-42,630
Closed -$340K – 1070
2018
Q4 		$340K Sell
42,630
-27,320
-39% -$394K ﹤0.01% 780
2018
Q3 		$1.35M Buy
69,950
+8,019
+13% +$146K 0.01% 518
2018
Q2 		$1.12M Buy
61,931
+40,056
+183% +$591K 0.01% 587
2018
Q1 		$233K Buy
21,875
+6,287
+40% +$101K ﹤0.01% 645
2017
Q4 		$657K Buy
15,588
+11,369
+269% +$510K ﹤0.01% 583
2017
Q3 		$232K Buy
+4,219
New +$712K ﹤0.01% 737
2017
Q2 		– Sell
-4,800
Closed -$574K – 988
2017
Q1 		$574K Buy
+4,800
New +$503K ﹤0.01% 602

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SIOX Position: Q1 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2022, closing a stake of 18,066 shares — an estimated $23K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SIOX in Q1 2017 and held it in 12 quarters. The position peaked at $1.35M in Q3 2018. 41 funds tracked by Wall St. Rank hold SIOX as of Q1 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 18,066 Sio Gene Therapies Inc. Common Stock shares in Q1 2022, an estimated $23K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2017 and held it in 12 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Sio Gene Therapies Inc. Common Stock position peaked at $1.35M in Q3 2018.
  • 41 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2022, filed 12 May 2022.